CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
儿童脑肿瘤的 CAR-T 细胞治疗：现状与未来
英文原题：CAR-T cells for pediatric brain tumors: Present and future.
查看英文原题
CAR-T cells for pediatric brain tumors: Present and future.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T（CAR-T）细胞目前仅获批用于儿童和成人的B细胞恶性肿瘤。尽管缺乏强有力的证据批准这种细胞免疫疗法用于儿童实体瘤，但在儿童脑肿瘤治疗中，这种方法正受到越来越多的关注。在确定肿瘤抗原作为靶点后，首批临床试验显示，对于此类肿瘤类型，CAR-T 细胞在一定程度上产生了临床和生物学反应。此外，近期多项临床前研究发现了新的有吸引力的靶点和抗原组合策略，以及局部区域给药后更优的肿瘤 trafficking。我们在此综述当前儿童脑肿瘤CAR-T 细胞临床开发所基于的临床前和临床知识。
展开英文摘要原文
Chimeric Antigen Receptor T (CAR-T) cells are currently approved for B cell malignancies only, in children and adults. Despite a lack of robust evidence to approve such cellular immunotherapy for pediatric solid tumors, there is a growing interest for this approach in the treatment of pediatric brain tumors.
Following the identification of tumor antigens as targets, the first clinical trials demonstrated some degree of clinical and biological responses to CAR-T cells for such tumor types. Additionaly, several preclinical studies have recently identified new attractive targets and antigen combination strategies, along with a superior tumor trafficking following locoregional administration.
We review here the preclinical and clinical knowledge at the basis of the current clinical development of CAR-T cells for pediatric brain tumors.
论文信息
- 作者
- Leruste A、Beccaria K、Doz F
- 单位
- PSL Research University, SIREDO Oncology Center (Care, Innovation and Research for Children and AYA with Cancer), Institut Curie, Paris, France. Electronic address: amaury.leruste@curie.fr.France
- 文献类型
- 综述
- 期刊
- Bulletin du cancer2021 Oct
- 原文标识
- PubMed 34920793 · DOI 10.1016/j.bulcan.2021.06.002